Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics issues $750 million of 1.75% convertible notes due 2031

Neutral Impact 4 of 5 financing Written later

On September 19, 2025, Cytokinetics issued $750.0 million of 1.75% convertible senior notes due October 1, 2031, including the full $100.0 million option granted to the initial purchasers. The company estimates net proceeds of about $729.4 million, and expects to use about $402.5 million in cash, plus 2,168,806 new common shares, to exchange about $399.5 million of its 3.50% notes due 2027, which extends that debt to 2031. Conversion at the initial price of about $68.42 per share could dilute existing shareholders if the notes are converted into shares.

Key points

  • $750.0 million principal issued September 19, 2025, including the full $100.0 million option
  • About $399.5 million of 3.50% 2027 notes to be exchanged for 2,168,806 shares plus about $402.5 million in cash
  • Initial conversion price of about $68.42, a 37.5% premium to the $49.76 closing price on September 16, 2025
  • Company may not redeem the notes before October 6, 2028

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECSep 19, 2025, 7:22 PM ET
Accession number0001193125-25-209437

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation3.02 Unregistered Equity Sale8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 19, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.